Similarly, in the KRAS G12C-mutant CT26 syngeneic mouse model, although MRTX849 monotherapy significantly inhibited tumor growth and induced partial tumor regression, combination therapy with an anti-PD-1 antibody dramatically enhanced therapeutic efficacy (144). The gene discussed is KRAS; the disease is neoplasm.